Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Considers Sodium Picosulfate For OTC Laxatives Monograph Inclusion

This article was originally published in The Tan Sheet

Executive Summary

FDA has announced a call for data for safety and effectiveness information on sodium picosulfate up to 10 mg as a laxative single active ingredient
Advertisement

Related Content

In Brief
Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA
Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA
Phenolphthalein Banned In OTC Laxatives Effective Jan. 28

Topics

Advertisement
UsernamePublicRestriction

Register

PS099493

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel